Information Provided By:
Fly News Breaks for April 19, 2017
PTLA
Apr 19, 2017 | 07:06 EDT
Citi analyst Yigal Nochomovitz says his analysis of FDA precedence further supports approval of Portola Pharmaceuticals' novel blood thinner betrixaban. The FDA decision date is June 24. Two of the 29 drugs that were approved under Priority Review and no panel also missed their primary endpoints, Nochomovitz tells investors in a research note. He keeps a Buy rating on Portola with a $51 price target.
News For PTLA From the Last 2 Days
There are no results for your query PTLA